Surfactant Levels in the Lungs of COVID-19 Patients

Zealand University Hospital

Status

Unknown

Conditions

To Assess Surfactant Levels in Lung Fluid

Treatments

Diagnostic Test: Surfactant assessment

Study type

Observational

Funder types

Other

Identifiers

NCT04609488

SJ-859x

Details and patient eligibility

About

NAME of STUDY: Surfactant levels in the lungs of COVID-19 patients BACKGROUND

Infection with SARS-CoV-2 may induce respiratory failure.
COVID-19 associated respiratory failure may require ventilatory support.
SARS-CoV-2 uses alveolar type II cells for virus replication.
Alveolar type II cells are responsible for surfactant production and lack of surfactant causes respiratory failure in preterm neonates.
Lack of surfactant may play role for respiratory failure in COVID-19 patients DESIGN Exploratory prospective study design without therapeutic intervention of any kind. Lung fluid will be donated as part of standard care procedures.

HYPOTHESIS Surfactant is measurable in tracheal secretions by mid-infrared FTIR spectroscopy determined surfactant spectra. Surfactant is reduced in COVID-19 patients requiring ventilator support as compared to non- COVID-19 patients. Dysfunctional surfactant in COVID-19 patients regain its function when respiratory function improves.

POPULATION Main population is patients with COVID-19 pneumonia that requires ventilatory support.

OUTCOME MEASURES Primary outcome is the level of surfactant in lung fluid as obtained by tracheal suction.

SAMPLE SIZE In total 30 patients will be included: twenty COVID-19 patients and 10 non-COVID-19 patients.

Enrollment

30 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients positive for coronavirus 2 (SARS-CoV-2) AND
Respiratory failure requiring mechanical ventilation support OR respiratory failure requiring oxygen supplementation AND
Age > 18 years AND
Permission from next of kin

Exclusion criteria

Inability to obtain TS or BL as determined by clinical judgement by responsible clinician. Patients with known surfactant dysfunction (such as mutations in the SFTPB or ABCA3 gene). Imminent expected death within 24 hours. Stage 4 severe chronic kidney disease or requiring dialysis. Liver failure. Anticipated transfer to another hospital within 72 hours. Participation in another study which in the opinion of the investigator would prevent enrollment for safety purposes.